Completed PHASE3 INTERVENTIONAL 2-arm NCT04935879

A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

Sponsor: Pfizer

Conditions Sickle Cell Disease Vaso-occlusive Crisis Vaso-occlusive Pain Episode in Sickle Cell Disease

Interventions Inclacumab Placebo

Updated 16 times since 2021 Last updated: Nov 17, 2025 Started: Oct 4, 2021 Primary completion: Jun 6, 2024 Completion: Jun 6, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Sickle Cell Disease and Vaso-occlusive Crisis and is currently completed. Pfizer leads this study, which shows 16 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

16 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Jan 2026 [monthly]

Completed PHASE3
May 2025 — Sep 2025 [monthly]

Completed PHASE3
Dec 2024 — May 2025 [monthly]

Completed PHASE3
Oct 2024 — Dec 2024 [monthly]

Completed PHASE3

▶ Show 11 earlier versions

Sep 2024 — Oct 2024 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3
Oct 2023 — Apr 2024 [monthly]

Active Not Recruiting PHASE3
Aug 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Mar 2023 — Aug 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Mar 2023 [monthly]

Recruiting PHASE3
Sep 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3
Dec 2021 — Jul 2022 [monthly]

Recruiting PHASE3
Sep 2021 — Dec 2021 [monthly]

Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abuja, Nigeria , Adana, Turkey (Türkiye) , Ann Arbor, United States , Barranquilla, Colombia , Boston, United States , Cairo, Egypt , Calabar, Nigeria , Chicago, United States , Créteil, France , Durham, United States and 30 more locations